Amphiphilic modification of human lysozyme enhances its ability to inhibit Aβ42 aggregation
Chemistry Letters · 01.08.2026 · 55 (8)
DOI: 10.1093/chemle/upag146 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry Letters, online erschienen am 06.08.2026. Verfasst von Tomonori Waku und 6 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Human lysozyme (hLYZ) was sequentially PEGylated, conjugated with ethylenediamine, and propionylated to yield PEGylated, cationic, and amphiphilic derivatives, respectively. The ability of these derivatives to inhibit amyloid β 42 (Aβ42) aggregation was evaluated and compared with that of unmodified hLYZ. Among the hLYZ derivatives examined, amphiphilic hLYZ showed the strongest inhibition of Aβ42 aggregation. These results suggest that amphiphilic modification of hLYZ through the introduction of polyethylene glycol (PEG) and hydrophobic groups may be a useful strategy for improving its ability to inhibit Aβ42 aggregation.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Waku, T., Tokazu, R., Hori, T., Okuda, M., Sugimoto, H., Matsuo, K., & Kobori, A. (2026). Amphiphilic modification of human lysozyme enhances its ability to inhibit Aβ42 aggregation. Chemistry Letters, 55(8). https://doi.org/10.1093/chemle/upag146
Vancouver
Waku T, Tokazu R, Hori T, Okuda M, Sugimoto H, Matsuo K, et al. Amphiphilic modification of human lysozyme enhances its ability to inhibit Aβ42 aggregation. Chemistry Letters. 2026;55(8). doi:10.1093/chemle/upag146
BibTeX
@article{Waku2026,
author = {Waku, Tomonori and Tokazu, Rina and Hori, Takaki and Okuda, Michiaki and Sugimoto, Hachiro and Matsuo, Kazuya and Kobori, Akio},
title = {Amphiphilic modification of human lysozyme enhances its ability to inhibit Aβ42 aggregation},
journal = {Chemistry Letters},
year = {2026},
volume = {55},
number = {8},
doi = {10.1093/chemle/upag146}
}
EUVIMED